Simoa (Single Molecule Array)
- Most sensitive platform for NfL detection
- Detection limit: ~0.04 pg/mL
- Enables blood-based testing with high precision
- Widely used in clinical research and trials
ECLOA (Electrochemiluminescence)
- Ultrasensitive immunoassay technology
- Comparable sensitivity to Simoa
- Used in automated laboratory platforms
- Good for high-throughput testing
ELISA (Enzyme-Linked Immunosorbent Assay)
- Traditional immunoassay method
- Higher detection limit than Simoa/ECLOA
- More accessible but less sensitive for blood NfL ## Biomarker Role NfL is a marker of axonal damage and neurodegeneration. When neurons or their axons are injured, NfL is released into the extracellular space and can be measured in cerebrospinal fluid and blood. ### Mechanism of Release 1. Axonal injury causes membrane disruption 2. NfL proteins leak into interstitial fluid 3. Diffusion into CSF and bloodstream 4. Detection via ultrasensitive immunoassays ## Clinical Applications ### Alzheimer's Disease (AD) - Elevated CSF NfL in AD patients compared to controls[1] - Correlates with MMSE scores and disease progression[2] - Higher levels associated with rapid cognitive decline[3] - May help differentiate AD from other dementias[4] ### Parkinson's Disease (PD) - CSF NfL elevated in PD, especially in PIGD subtype - Predicts motor progression and cognitive decline - Higher levels correlate with Braak stage - May distinguish PD from atypical parkinsonisms ### Amyotrophic Lateral Sclerosis (ALS) - Key biomarker for ALS diagnosis and progression - Elevated in ALS vs. other neurological conditions - Predicts survival and disease progression rate - Used in clinical trials as pharmacodynamic marker ### Multiple System Atrophy (MSA) - Higher CSF NfL than PD - Helps differentiate MSA from PD - Correlates with disease severity ### Frontotemporal Dementia (FTD) - Elevated in FTD, especially ALS-FTD - Distinguishes FTD from AD - Correlates with disease progression ## Diagnostic Utility ### Cut-off Values (approximate) | Condition | CSF NfL (pg/mL) | Plasma NfL (pg/mL) | |-----------|------------------|---------------------| | Normal | < 500 | < 15 | | AD | 500-2000 | 15-50 | | PD | 400-1500 | 10-30 | | ALS | 1000-8000 | 30-200 | | FTD | 500-3000 | 15-80 | Note: Values vary by assay and laboratory ### Sensitivity and Specificity | Disease | Sensitivity | Specificity | |---------|-------------|-------------| | ALS | 85-95% | 80-90% | | AD | 70-85% | 75-90% | | PD | 65-80% | 70-85% | ## Comparison with Other Biomarkers | Biomarker | What it Measures | Best For | |-----------|------------------|----------| | NfL | Axonal damage | ALS, progression | | p-tau | Tau pathology | AD diagnosis | | Aβ42/40 | Amyloid pathology | AD diagnosis | | Neurogranin | Synaptic damage | AD, cognitive decline | | sTREM2 | Microglial activation | AD, disease modification | ## CBS and PSP (4R Tauopathies) Neurofilament Light Chain (NfL) is a promising biomarker for tracking neurodegeneration in CBS and PSP, showing elevated levels that correlate with disease severity and progression. ### Levels in CBS and PSP Multiple studies have demonstrated significantly elevated NfL levels in both CBS and PSP compared to healthy controls: - CBS patients: CSF NfL levels are markedly elevated, often exceeding those seen in PSP and AD - PSP patients: Elevated CSF and plasma NfL compared to controls, with levels correlating with disease severity - Discriminative value: NfL can help distinguish CBS from PSP, with CBS typically showing higher levels ### Diagnostic Utility | Comparison | Sensitivity | Specificity | Key Findings | |------------|-------------|-------------|--------------| | CBS vs. Controls | 85-90% | 90-95% | Significantly elevated | | PSP vs. Controls | 80-85% | 85-90% | Moderately elevated | | CBS vs. PSP | 75-80% | 70-75% | CBS > PSP | ### Correlation with Disease Progression NfL levels in CBS and PSP correlate with: - Disease duration: Longer disease = higher NfL - Severity scores: Higher PSP-RS/CBD-RS scores correlate with elevated NfL - Motor impairment: UPDRS Part III scores show positive correlation - Cognitive decline: MMSE and executive function scores inversely correlate - Brain atrophy: MRI-measured atrophy rates correlate with NfL levels ### Comparison with Other Tauopathies | Disorder | CSF NfL Level | Relative to CBS | |----------|---------------|-----------------| | CBS | Very High | Reference | | PSP | High | 70-80% of CBS | | AD | Moderate | 50-60% of CBS | | PD | Low | 30-40% of CBS | | Controls | Low | 20-30% of CBS | ### Clinical Implementation Advantages: - Widely available assay (Simoa, ELISA) - Relatively non-invasive (plasma/serum testing possible) - Good reproducibility across laboratories - Tracks disease progression useful for clinical trials Limitations: - Not specific to tauopathies (elevated in any neurodegeneration) - Lack of standardized cutoffs for CBS/PSP - Variable baseline levels require longitudinal tracking Practical considerations: - Plasma NfL is less invasive than CSF collection - Collect samples in the morning to minimize diurnal variation - Compare to age-adjusted reference ranges - Use for monitoring rather than diagnostic specificity ### Research Directions Current research focuses on: - Longitudinal studies: Tracking NfL change over time - Treatment response: NfL as outcome measure in clinical trials - Subtype differentiation: NfL patterns in PSP variants - Combination biomarkers: NfL + p-tau for better discrimination
flowchart TD
%% Blue = Triggers/Inputs
A["Normal Neuron"]:::blue --> B["NfL in Axon"]:::blue
%% Orange = Intermediate steps
C1["Trauma/<br/>Neurodegeneration"]:::orange
C2["Protein<br/>Aggregation"]:::orange
C3["Oxidative<br/>Stress"]:::orange
%% Red = Pathological events
D["Membrane<br/>Disruption"]:::red
%% Blue = Outputs
E["NfL Release into<br/>Interstitial Fluid"]:::blue
F["Diffusion into<br/>CSF"]:::blue
G["Cross Blood-<br/>Brain Barrier"]:::blue
H["Detection in<br/>Blood"]:::blue
I["CSF NfL<br/>Measurement"]:::blue
J["Blood NfL<br/>Measurement"]:::blue
%% Yellow = Decision points
K["Diagnostic<br/>Biomarker"]:::yellow
L["Monitoring<br/>Biomarker"]:::yellow
%% Green = Outcomes
M["AD/PD/ALS/FTD/HD<br/>Diagnosis"]:::green
N["Disease Progression<br/>Tracking"]:::green
%% Connections
B --> C1
B --> C2
B --> C3
C1 --> D
C2 --> D
C3 --> D
D --> E
E --> F
E --> G
G --> H
F --> I
H --> J
I --> K
J --> L
K --> M
L --> N
%% Click links
click A "/cell-types/neurons" "Neurons"
click M "/diseases/alzheimers-disease" "Alzheimer's Disease"
click M "/diseases/parkinsons-disease" "Parkinson's Disease"
click M "/diseases/als" "ALS"
click N "/mechanisms/neurodegeneration" "Neurodegeneration"
%% Color definitions
classDef blue fill:#e1f5fe,stroke:#0277bd,stroke-width:2px
classDef orange fill:#fff3e0,stroke:#ef6c00,stroke-width:2px
classDef red fill:#ffcdd2,stroke:#c62828,stroke-width:2px
classDef yellow fill:#fff9c4,stroke:#f9a825,stroke-width:2px
classDef green fill:#c8e6c9,stroke:#2e7d32,stroke-width:2px
Simoa (Single Molecule Array)
- Most sensitive platform for NfL detection
- Detection limit: ~0.04 pg/mL
- Enables blood-based testing with high precision
- Widely used in clinical research and trials
ECLOA (Electrochemiluminescence)
- Ultrasensitive immunoassay technology
- Comparable sensitivity to Simoa
- Used in automated laboratory platforms
- Good for high-throughput testing
ELISA (Enzyme-Linked Immunosorbent Assay)
- Elevated NfL in HD patients compared to healthy controls
- Correlates with disease progression and functional decline
- Higher baseline NfL predicts faster motor and cognitive decline
- Can detect premanifest HD individuals before clinical diagnosis
- NfL levels correlate with CAG repeat length in some studies
- May help track response to disease-modifying therapies
| Property |
Blood NfL |
CSF NfL |
| Invasiveness |
Minimal (venipuncture) |
High (lumbar puncture) |
| Clinical Utility |
Preferred for monitoring |
Gold standard for diagnosis |
| Correlation |
Strong (r > 0.8) with CSF |
Reference standard |
| Timing |
Reflects acute axonal injury |
More stable baseline |
| Clinical Setting |
Routine monitoring |
Specialist evaluation |
- Blood NfL is now preferred for disease monitoring and clinical trials due to ease of sampling
- CSF NfL remains important for diagnostic workup and research standardization
- Blood and CSF levels correlate strongly, allowing blood-based monitoring
- Age-adjusted reference ranges are critical for interpretation
- Combination with other biomarkers (e.g., p-tau, α-synuclein) improves diagnostic accuracy
- Khalil et al., Neurofilament light chain as a biomarker in neurodegeneration (2024)
- Bacioglu et al., Neurofilament in blood and CSF (2024)
- Gaetani et al., NfL in neurodegenerative diseases (2024)
- Lewczuk et al., CSF and blood NfL comparison (2024)
- Milanesi et al., NfL clinical implementation (2025)
- Park et al., Blood NfL in AD and PD (2025)
- Barro et al., NfL in disease progression (2024)
- Preische et al., Serum NfL predicts neurodegeneration (2024)